Thiogenesis Therapeutics, Corp. (TSXV: TTI)

Market Cap	27.31M
Revenue (ttm)	n/a
Net Income (ttm)	-4.09M
Shares Out	45.51M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,800
Open	0.620
Previous Close	0.600
Day's Range	0.620 - 0.620
52-Week Range	0.520 - 1.060
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 28, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company’s lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Patrice Rioux
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TTI